Edition:
India

Cellectis SA (CLLS.OQ)

CLLS.OQ on NASDAQ Stock Exchange Global Market

24.29USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$24.29
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
68,227
52-wk High
$35.07
52-wk Low
$16.16

Select another date:

Tue, Sep 5 2017

Cellectis shares slump as death puts cell therapy tests on hold

LONDON French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment similar to Novartis's recently approved Kymriah, has been forced to suspend testing following a patient death.

BRIEF-Cellectis says FDA places clinical hold of UCART123 studies following fatality

* ANNOUNCED TODAY HAVING RECEIVED NOTICE FROM FDA THAT CLINICAL HOLD WAS PLACED ON BOTH UCART123 ONGOING PHASE 1 STUDIES IN ACUTE MYELOID LEUKEMIA (AML) AND IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

BRIEF-Cellectis announces first patient dosed in clinical trial on UCART123

* ANNOUNCED ON THURSDAY, UCART123'S ADMINISTRATION TO FIRST PATIENT WITH BPDCN IN PHASE I CLINICAL TRIAL AT MD ANDERSON CANCER CENTER

BRIEF-Cellectis reports Q2 operating loss of 18.0 million euros

* SAID ON WEDNESDAY FIRST AML PATIENT TREATED WITH UCART123 ENROLLMENT ONGOING

BRIEF-Molmed signs development and production agreement with Cellectis

* SIGNS WITH CELLECTIS AGREEMENT FOR DEVELOPMENT AND PRODUCTION IN THE FIELD OF ALLOGENEIC CAR-T PRODUCTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cellectis is granted patent for CRISPR use in T-cells

* ANNOUNCED ON MONDAY ABOUT THE GRANT BY THE EUROPEAN PATENT OFFICE OF PATENT NO. EP3004337 FOR THE INVENTION OF USING RNA-GUIDED ENDONUCLEASES, SUCH AS CAS9 OR CPF1 FOR THE GENETIC ENGINEERING OF T-CELLS

BRIEF-Cellectis announces proposed Calyxt IPO of $100.0 million

* CELLECTIS: CALYXT ANNOUNCES PROPOSED INITIAL PUBLIC OFFERING OF $100.0 MILLION

BRIEF-Cellectis announces first administration in Phase I clinical study in AML for UCART123

* ANNOUNCED ON TUESDAY FIRST ADMINISTRATION IN THE PHASE I CLINICAL STUDY IN ACUTE MYELOID LEUKEMIA (AML) FOR ITS INVESTIGATIONAL PRODUCT UCART123

Select another date: